About the Authors
- David S. Wald
-
* E-mail: d.s.wald@qmul.ac.uk
Affiliation Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
- Jonathan P. Bestwick
-
Affiliation Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
- Lewis Raiman
-
Affiliation Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
- Rebecca Brendell
-
Affiliation Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
- Nicholas J. Wald
-
Affiliation Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom
Competing Interests
David Wald has read the journal's policy and the authors of this manuscript have the following competing interests: Nicholas Wald jointly holds US, European and Canadian patents (EU1272220 priority date 10 April 2000) for a combination pill for the prevention of cardiovascular disease and together with David Wald is a shareholder in Polypill Ltd. Astra Zeneca part-funded the INTERACT trial. None of these disclosures alter the authors' adherence to all PLOS ONE policies on data sharing and materials.
Author Contributions
Conceived and designed the experiments: DSW NJW. Performed the experiments: DSW LR RB. Analyzed the data: DSW JPB NJW. Wrote the paper: DSW JPB LR RB NJW.